New Haven: Modifi Biosciences, Inc., has announced that the company has been acquired by Merck, known as MSD outside of the United States and Canada. “In founding Modifi Biosciences, we sought to ...

The Gardasil franchise is the company's second largest sales driver behind Keytruda, and Merck remains steadfast it can garner more than $11 billion from the key product in 2030. Fewer than 10% of ...

Davis, chairman and chief executive officer, Merck. “Our pipeline is advancing and expanding, demonstrating our success in creating a sustainable innovation engine, and positioning Merck with a more ...

and medical capacity building in other specialties like respiratory care, acute care, emergency pediatric and neonatal care, and more. Additionally, a community awareness session, Merck Foundation ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

NEW YORK – Moderna and Merck will test their personalized neoantigen cancer vaccine V940 with Merck's checkpoint inhibitor Keytruda (pembrolizumab) in certain non-small cell lung cancer patients in a ...

Merck, a leading pharmaceutical company, has embarked on a digital transformation by signing a Memorandum of Understanding with technological innovator Siemens. This partnership will propel digital ...

Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair processes. Modifi Biosciences, a spin out of Yale University founded in 2021, ...

Merck has acquired Modifi Biosciences, a Connecticut-based biotech, for up to $1.3bn. The acquisition strengthens Merck’s oncology portfolio as the company looks to offset revenue losses from the ...